We recommend supplementing with aminoguardidine for lens, retinal and optic nerve support.
Aminoguanidine is an anti-glycating agent meaning that it inhibits the ‘cross-linking’ (or glycosylation) of proteins which may cause or at least contribute to many of the problems of old age, including eye problems such as cataracts, glaucoma and macular degeneration.
Cross-linking is the process that causes food to turn yellow and become tough with age. Similarly with humans, cross-linking may be responsible for many aging conditions, thickening of the arteries, some cancers and damage to the immune system.
Aminoguanidine may have the potential to slow the aging process by protecting the proteins that make up the human body. These include the skin proteins (collagen and elastin), eye lens, nerve and kidney proteins. All these vital proteins deteriorate with advancing age, even more so in diabetics who have 2-3 times the number of cross-linked proteins than non-diabetics.
Serving Size: 1 tablet
Servings Per Container: 100
Amount Per Serving - % Daily Value
Aminoguanidine - 75 mg
*Pyridoxine - 10 mg 500%
*Daily value not established
Other ingredients: Microcrystalline Cellulose, Carboxymethyl Cellulose Sodium, Calcium Phosphate, Magnesium Stearate.
Suggested Use: Take 75 mg two, three or four times a day, spread out over different times as the Aminoguanidine has a half-life of approximately 4-hours.
Store in a cool, dry place away from sunlight.
KEEP OUT OF THE REACH OF CHILDREN.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, cure or prevent disease.
One study conducted on animals showed that Aminoguanidine prevented age-related enlargement of the heart reducing the membrane surface area by 30%. In addition, the collagen content of their arterial walls was increased by 24-30%.
Studies conducted at the University of Milan over the last 25 years have shown Aminoguanidine’s ability to reduce the ability of very low density lipoprotein (‘bad cholesterol’) to bind itself to blood vessel walls. In turn, blood platelets are less likely to coagulate and form dangerous clots.
Aminoguanidine has an ability to treat patients whose blood vessels are constricted by arteriosclerosis. In 1992 at the University of Milan, 11 patients with peripheral vascular disease were treated with Aminoguanidine. Due to the extent of their clogged blood vessesl, the patients could not walk for more than 500 yards. After treatment, the patients blood flow improved on average by 30% and the patients exercise abilities improved by 50% to 105%.
A number of different studies with diabetic rats indicate that Aminoguanidine administered rats have significantly superior survival rates than those who are untreated. Diabetic clinical trials with humans have also highlighted Aminoguanidine’s ability to prevent oxidative modification of low-density lipoproteins (LDL) and inhibit the formation of atherosclerotic plaques.
This new formulation contains 10mg of B6 in each tablet in a hydrochloride (HCL) based tablet. This is more expensive than a bicarbonate based version, but the HCL is more soluble, less irritating and is the type used in the clinical trials.
Possible side effects are nausea and headaches. As human clinical trials are still relatively limited, dosages shouldn't be exceeded unless under the supervision of a physician.
Aminoguanidine can inhibit the uptake of vitamin B6, so a B6 supplement is recommended while using Aminoguanidine.